Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baclofen for positive and negative symptoms in schizophrenia
IRCT20250312065047N1Phase 2Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Baclofen + risperidone with Placebo + risperidone (2 arms). Primary endpoints: Structured Clinical Interview for DSM, Positive and Negative Syndrome Scale and 2 more. Started Apr 2025; status: completed.
02
Drugs
baclofen
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20250312065047N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250312065047N1.